Skip Navigation


NDT Plus Advance Access originally published online on April 22, 2009
NDT Plus 2009 2(4):295-297; doi:10.1093/ndtplus/sfp045
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2/4/295    most recent
sfp045v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Georgaki-Angelaki, E.
Right arrow Articles by Anagnostakou, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2009]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Olmesartan medoxomil-induced acute renal failure in a premature newborn following maternal exposure during pregnancy: a case report and review of the literature

Eleni Georgaki-Angelaki1, Nicolaos Stergiou1, Ekaterini Naoum2, Ioannis Papassotiriou3 and Marina Anagnostakou2

1 Department of Pediatric Nephrology
2 Neonatal Intensive Care Unit
3 Department of Clinical Biochemistry, ‘Aghia Sophia’ Children's Hospital, Athens 11527, Greece

Correspondence: Correspondence and offprint requests to: Ioannis Papassotiriou; E-mail: biochem{at}paidon-agiasofia.gr


  Abstract

Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II (AT II) receptor blockers (ARBs) are widely used antihypertensives with well-recognized renoprotective and cardioprotective effects. Although treatment with these agents generally does not result in adverse metabolic consequences, their use during human pregnancy has been associated with negative reactions. Here we report a premature baby with a history of oligohydramnios and maternal exposure to the ARB olmesartan medoxomil who was transferred to our institution with acute renal failure. Conservative treatment with diuretics and meticulous management of fluids and electrolytes resulted in an improvement in renal function in the patient. We conclude that olmesartan medoxomil may cause reversible renal failure in premature neonates.

Key Words: acute renal failure • oligohydramnios • olmesartan medoxomil

Received for publication April 1, 2009. Accepted for publication April 3, 2009.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.